Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
NCT07021937 on ClinicalTrials.gov · last registry update 2026-07-02
A small phase 3 — 120 participants, against a typical 424. Due to report 30 April 2031. Primary outcome, as filed: blood oxygen-level dependent signal. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 120
- Started
- 2026-06-15
- Primary completion
- 2031-04-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
blood oxygen-level dependent signal
Conditions studied
Obesity/Therapy
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.